Solventum (NYSE:SOLV) Given Buy Rating at BTIG Research

NodeGuardian · 2026-03-07T11:40:35+00:00

BTIG Research maintains a "buy" rating for Solventum (NYSE:SOLV) with a $100 price target, anticipating a 29.45% upside. This follows strong Q4 earnings that exceeded estimates, robust demand in wound care and sterilization, a $1 billion buyback plan, and positive FY 2026 guidance.

NodeGuardian

2026-03-07 11:40:35

Abstract generation in progress

BTIG Research has reiterated a “buy” rating for Solventum (NYSE:SOLV), setting a price target of $100.00, suggesting a potential upside of 29.45%. This positive outlook follows Solventum’s strong fourth-quarter earnings, where the company surpassed consensus estimates for both EPS and revenue, driven by robust demand in wound care and sterilization products. The company also announced a $1 billion stock buyback plan and issued optimistic FY 2026 guidance, reinforcing analyst confidence despite potential margin pressures.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes